SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

September 13, 2010 07:00 ET

SciClone Pharmaceuticals to Present at Two Investor Conferences in September

Rodman & Renshaw Global Investment Conference on Tuesday, September 14 at 12:30 pm ET; UBS Global Life Sciences Conference on Wednesday, September 22 at 3:00 pm ET

FOSTER CITY, CA--(Marketwire - September 13, 2010) -  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Global Investment Conference, and UBS Global Life Sciences Conference.  SciClone's executives will present a corporate overview and business update at each conference.

  Rodman & Renshaw Global Investment Conference
  Tuesday, September 14; 12:30 pm ET
  New York City, NY
  Presenter: Friedhelm Blobel, PhD, President and CEO
   
  UBS Global Life Sciences Conference
  Wednesday, September 22; 3:00 pm ET
  New York City, NY
  Presenter: Gary Titus, Senior Vice President and CFO

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com

About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, China-centric specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. The Company is focused on continuing sales growth, particularly in China, and a clinical development strategy with prudently managed costs. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. In addition to further studying thymalfasin's use as a vaccine enhancer, SciClone is planning to evaluate SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer; and is evaluating SCV-07 in a phase 2b trial for the treatment of HCV. The Company also has exclusive commercialization and distribution rights in China to a novel treatment for advanced liver cancer, DC Bead®, currently under review by Chinese regulatory agencies. Additionally, SciClone owns exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China, including Hong Kong and Macau, and Vietnam. The Company will seek regulatory approval for the product, commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery, in each of these markets. For additional information, please visit www.sciclone.com.

Focetria is a registered trademark of Novartis AG Corporation.

DC Bead is a registered trademark of Biocompatibles UK Limited.

RapidFilm is a trademark of Labtec Gesellschaft für technologische Forschung und Entwicklung mbH.